title: Vascular protectants for the treatment of atherosclerosis.
abstract: AGI-1067, the monosuccinic acid ester of probucol, is a phenolic antioxidant member of a novel class of agents termed vascular protectants. It has strong antioxidant properties, equipotent to those of probucol, and anti-inflammatory properties. It inhibits gene expression of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 and has been effective at preventing atherosclerosis in all tested animal models. It also improved luminal dimensions of reference segments in the percutaneous coronary intervention (PCI) vessels in the CART-1 clinical trial, which suggests a direct anti-atherosclerosis effect. Two important trials that test the antioxidant/anti-inflammatory hypothesis are ongoing with AGI-1067: the Canadian Atherosclerosis and Restenosis Trial, which assesses its value for the reduction of both atherosclerosis progression in non-PCI vessels and post-PCI restenosis, and the Aggressive Reduction of Inflammation Stops Events trial, which is evaluating the effects of AGI-1067 on hard cardiovascular outcomes.
authors.affiliation: Montreal Heart Institute, 5000 Belanger Street, Montreal, PQ, H1T 1C8, Canada. tardifjc@icm.umontreal.ca
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tardif
authors.forename: Jean
authors.initials: J
authors.lastname: Grégoire
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Lavoie
authors.forename: Philippe L
authors.initials: PL
authors.lastname: L'Allier
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000517:prevention & control*; D006801:Humans; D011341:Probucol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D020011:Protective Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
chemical_list: D000975:Antioxidants; D020011:Protective Agents; C471047:succinobucol; D011341:Probucol